Close Menu

NEW YORK (GenomeWeb) – Santa Cruz, California-based Two Pore Guys said today that it is collaborating with oncologists at the University of California, San Francisco to develop a liquid biopsy assay. The UCSF team plans to evaluate Two Pore Guys' handheld nanopore platform for detecting circulating tumor DNA, and specifically, for detecting a KRAS mutation from blood and urine samples.

Andrew Ko, a professor of hematology and oncology and gastrointestinal cancer specialist at the UCSF Helen Diller Family Comprehensive Cancer Center, will lead the study.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Apr
23
Sponsored by
N-of-One

In 2016, the Association for Molecular Pathology (AMP), in partnership with the College of American Pathologists (CAP) and American College of Molecular Genetics (ACMG), launched a set of guidelines meant to set industry standards for reporting of molecular diagnostic test results in oncology, using a tier-based system and defined levels of evidence. 

Apr
24
Sponsored by
Biocrates

This webinar will provide a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.